Table 2.
The proportion of participants responding to full‐length C‐peptide (PI33‐63) is higher than for any other proinsulin or HIP epitope.
| Epitope | Healthy controls (%) | AB‐negative (%) | AB‐positive (%) | T1D ≤ 3 months (%) | T1D > 3 months (%) |
|---|---|---|---|---|---|
| PI33‐63 | 4/16 (25%) # , **** | 7/9 (78%) | 10/17 (58%) | 28/32 (88%) | 13/40 (33%) # , **** |
| PI48‐62 | 1/14 (7%) # , * | 6/9 (75%) | 9/17 (53%) | 13/29 (45%) | 9/37 (24%) |
| PI40‐52 | 0/13 (0%) # , *** | 6/8 (75%) | 3/17 (18%) | 12/28 (43%) | 8/38 (21%) |
| hEL:A‐chain | 1/14 (7%) # , * | 4/8 (50%) | 7/17 (41%) | 13/28 (46%) | 10/38 (26%) |
| hEGGG:C‐pep | 0/14 (0%) # , *** | 3/8 (38%) | 4/17 (24%) | 12/26 (46%) | 10/35 (29%) |
| hEGGG:IAPP2 | 2/14 (14%) # , * | 3/8 (38%) | 3/17 (18%) | 12/25 (48%) | 8/37 (22%) |
The percentage of each group with CDI ≥ 3 to each auto‐antigenic epitope. The denominator indicates the number of participant samples in each group for which results are available with CDI calculated from the mean of unstimulated proliferation in triplicate experiments.
#
Comparison with T1D ≤ 3 months.
*
P < 0.05.
***
P < 0.001.
****
P < 0.0001, Fisher’s exact test.